This grant aims to support R01 applications investigating mechanisms by which COVID-19 interacts with and modulates Alzheimer’s Disease and related dementias (AD/ADRD) phenotypes. Proposals must utilize animal, cell culture, or human tissue models, incorporating AD/ADRD risk factors, pathologies, or comorbidities. Focus areas include: how COVID-19 impacts CNS pathology and cognition in existing AD/ADRD models; how it accelerates AD/ADRD pathology in prodromal stages; or how it predisposes for AD/ADRD, interacting with relevant comorbid conditions and risk factors at a cellular level. The objective is to understand how COVID-19 influences future AD/ADRD risk.
Opportunity ID: 353519
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-24-203 |
| Funding Opportunity Title: | Neuropathological Interactions Between COVID-19 and ADRD (R01 – Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Apr 12, 2024 |
| Last Updated Date: | Apr 12, 2024 |
| Original Closing Date for Applications: | Oct 04, 2024 |
| Current Closing Date for Applications: | Oct 04, 2024 |
| Archive Date: | Nov 09, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $500,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education Native American tribal governments (Federally recognized) Others (see text field entitled “Additional Information on Eligibility” for clarification) For profit organizations other than small businesses Independent school districts Public housing authorities/Indian housing authorities State governments Special district governments City or township governments Small businesses Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This NOFO will solicit R01 applications that propose studies in animal, cell culture, and/or human tissue models to elucidate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. Either the model itself or the experimental readouts will be required to incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. To this end, proposals can focus on one or more of the following: – Mechanistic studies that address how COVID-19 impacts CNS pathology and cognitive outcomes when AD/ADRD pathology is already present (for example, in a model of AD/ADRD). – Mechanistic studies that address how COVID-19 accelerates AD/ADRD pathology and cognitive deficits in a prodromal model (early phase, pre-symptomatic). – Mechanistic studies that address how COVID-19 predisposes for AD/ADRD and/or interacts with relevant comorbid conditions and risk factors (cellular mechanisms that could potentially increase the risk for future AD/ADRD). |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-24-203.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 353519 Full Announcement-PAR-24-203 -> PAR-24-203-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00285851 | Sep 04, 2024 | Oct 04, 2024 | View |
Package 1
Mandatory forms
353519 RR_SF424_5_0-5.0.pdf
353519 PHS398_CoverPageSupplement_5_0-5.0.pdf
353519 RR_OtherProjectInfo_1_4-1.4.pdf
353519 PerformanceSite_4_0-4.0.pdf
353519 RR_KeyPersonExpanded_4_0-4.0.pdf
353519 PHS398_ResearchPlan_5_0-5.0.pdf
353519 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
353519 RR_Budget_3_0-3.0.pdf
353519 RR_SubawardBudget30_3_0-3.0.pdf
353519 PHS398_ModularBudget_1_2-1.2.pdf
353519 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
